罗格列酮对2型糖尿病患者血清抵抗素和脂联素的影响被引量：1

导出

摘要目的探讨罗格列酮对2型糖尿病患者血清抵抗素和脂联素水平的影响。方法将92例符合1999年WHO糖尿病诊断标准的初诊2型糖尿病患者，随机分为治疗组50例和对照组42例，两组均给予一般治疗，治疗组另外给予罗格列酮4mg，每日1次，口服，总疗程3个月，测定血糖和血清胰岛素及抵抗素、脂联素，以胰岛素抵抗指数模型评价组织胰岛素敏感性。结果ROS治疗3个月后，患者胰岛素抵抗指数及血清抵抗素水平均明显降低（P〈0．05或〈0．01），脂联素明显升高（P〈0．05）；与对照组比较有明显改善（P〈0．05）。结论罗格列酮能显著降低2型糖尿病患者胰岛素抵抗程度，改善糖代谢，可能与改善人血清抵抗素和脂联素水平有关。

作者于锡岭王广征

机构地区山东邹城兖矿集团有限公司总医院东院区聊城市传染病医院

出处《中国实用医刊》 2012年第22期105-106,共2页 Chinese Journal of Practical Medicine

关键词罗格列酮抵抗素脂联素 2型糖尿病

分类号 R587 [医药卫生—内分泌]

引文网络
相关文献

参考文献11

1Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin [ J]. Nat Clin Pract Cardiovasc Med, 2009,6 ( 1 ) :27-35.
2Zhu W, Cheng KK, Vanhoutre PM, et al. Vascular effects of adipoue- ctin : molecular mechanisms and potential therapeutic intervention [ J ]. Clin Sci (Lond) ,2008,114 (5) : 361-374.
3姚家明.罗格列酮治疗单纯期2型糖尿病的临床观察[J].中国社区医师（医学专业）,2010,12(33):86-87. 被引量：1
4张英,罗佐杰,陈青云,陈志云,梁杏欢,卢德成.2型糖尿病患者抵抗素水平及吡格列酮干预治疗的影响[J].临床内科杂志,2004,21(7):480-481. 被引量：5
5Steppan CM, Bailley ST, Bhat S, et al. The hormone reoistin links o- besity to diabetes [ J ]. Nature,2001,409 (10) : 307-312.
6Riedler J, Braun-Fahrlander C, Eder W. Exposure to farmiIlg in early life and development of asthma and allergy : a cross-sectional survey[ J]. Lancet,2008,358(9) :1129-1133.
7Kharroubi I, Rasschae J, Eizirik DL, et al. Expression of adiponectin receptors in pancreatic beta cells [ J ]. Biochemi Biophysi Res Connnu- ni,2003,312(4) :1118-1122.
8Broedl UC, Lehrke M, Fleiseher-Briehnaier E, et a; Genetic vari- ants of adiponectin receptor 2 are associated with increased adiponec- tin levels and decreased triglyeeride/VLDL levels in patients with met- abolic syndrome[ J]. Cardiovasc Diabetol, 2006,5 : 1 1.
9银艳,郭志新.罗格列酮对2型糖尿病大鼠心脏组织脂联素受体2单核趋化蛋白-1表达的影响[J].中国药物与临床,2010,10(11):1223-1226. 被引量：2
10Kilgore KS, Billin AN. PPARbeta/deha ligands as modulators of the inflammatory response [ J ]. Curt Opin Investig Drugs, 2008,9 ( 5 ) : 463-469.

二级参考文献23

1宁光,杨军,杨义生,张翼飞,顾卫琼,洪洁,李小英,陈名道,许曼音,陈家伦.脂肪细胞因子的临床和基础研究[J].国外医学（内分泌学分册）,2005,25(3):158-160. 被引量：40
2Yamauchi T,Kamon J,Ito Y,et al.Cloning of adiponectin receptors that mediate antimetabolic effects.Nature,2003,423:762-769.
3Hattori Y,Akimoto K,Gross SS,et al.Angiotensin-Ⅱ-inducod.oxidative stress elicits hypoadiponectinaemia in rats.Diabetologia,2005,48:1066-1074.
4Okamoto Y,Kihara S,Funahash IT,et al.Adiponectin:a key adipocytokine in metabolic syndrome.CAin Sci (Lond),2006,110 (3):267-278.
5Kharroubi I,Raeschaert J,Eizirik DL,et al.Expression of adiponectin receptors in pancreatic beta cells.Biechemi Biophysi Res Communi,2003,312(4):1118-1122.
6Broedl UC,Lehrke M,Fleischer-Brielmaier E,et al.Genetic variants of adiponectin receptor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome.Cardiovasc Diabetoi,2006,15 (5):11.
7Shibata R,Ouchi N,Ito M,et al.Adiponectin mediated medulation of hypertrophic signals in the heart.Nat Med,2004,10(12):1384-1389.
8Kamei N,TobeK,Suzuki R,et al.Overexpression of monecyte chemoat-tractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance.J Biol Chem,2006,281 (36):26602.
9Maeda N,Takahashi M,Funahashi T,et al.PPARgamma ligandsincrease expression and plasma concentratons of adiponectin,an adipese-derivedprctein.Diabetes,2001,50(9):2094-2099.
10Chinetti G,Zawadski C,Fruchart JC,et al.Expression of adiponectin receptors in human macrophages and regulation by agunists of the nuclear receptors PPAR gamma,and LXR.Biophys Res Commun,2004,314(2):151-158.